Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 11, 2019. The document serves as a transaction notification regarding a sale of ordinary shares by a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a regulatory disclosure of a specific securities transaction.
| Metric | Value |
|---|---|
| Transaction Type | Sale of Ordinary Shares |
| Instrument | Ordinary shares of 25 pence each (ISIN: GB0009252882) |
| Volume | 6,464 shares |
| Price | £15.57 per share |
| Transaction Date | February 8, 2019 |
| Exchange | London Stock Exchange (XLON) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a single transaction by an executive and does not compare financial results to prior periods.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a mandatory disclosure of an insider trade.
Key Facts for Investor Verification
- Executive Identity: The transaction was executed by Mr. R G Connor, President of Global Vaccines.
- Transaction Nature: This was an initial notification of a sale, not an amendment to a previous report.
- Market Context: The shares were sold on the London Stock Exchange at a price of £15.57.
- Scope Limitation: This filing does not reflect the company's overall financial health or strategic direction.